AP2004003074A0 - Adjuvanted antigenic meningococcal compositions - Google Patents

Adjuvanted antigenic meningococcal compositions

Info

Publication number
AP2004003074A0
AP2004003074A0 APAP/P/2004/003074A AP2004003074A AP2004003074A0 AP 2004003074 A0 AP2004003074 A0 AP 2004003074A0 AP 2004003074 A AP2004003074 A AP 2004003074A AP 2004003074 A0 AP2004003074 A0 AP 2004003074A0
Authority
AP
ARIPO
Prior art keywords
compositions
adjuvanted
meningococcal compositions
adjuvanted antigenic
antigenic meningococcal
Prior art date
Application number
APAP/P/2004/003074A
Other languages
English (en)
Inventor
Mariagrazia Pizza
Marzia Monica Giuliani
Original Assignee
Chiron Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Spa filed Critical Chiron Spa
Publication of AP2004003074A0 publication Critical patent/AP2004003074A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
APAP/P/2004/003074A 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions AP2004003074A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0129007.1A GB0129007D0 (en) 2001-12-04 2001-12-04 Adjuvanted antigenic meningococcal compositions
PCT/IB2002/005662 WO2003047619A2 (en) 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions

Publications (1)

Publication Number Publication Date
AP2004003074A0 true AP2004003074A0 (en) 2004-06-30

Family

ID=9926977

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2004/003074A AP2004003074A0 (en) 2001-12-04 2002-12-04 Adjuvanted antigenic meningococcal compositions

Country Status (11)

Country Link
US (2) US20060008476A1 (enExample)
EP (1) EP1448230B1 (enExample)
JP (2) JP4414226B2 (enExample)
AP (1) AP2004003074A0 (enExample)
AT (1) ATE485055T1 (enExample)
AU (1) AU2002353417A1 (enExample)
CA (1) CA2468935C (enExample)
CY (1) CY1111114T1 (enExample)
DE (1) DE60238075D1 (enExample)
GB (1) GB0129007D0 (enExample)
WO (1) WO2003047619A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9513371D0 (en) * 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
JP4763210B2 (ja) * 2000-02-28 2011-08-31 ノバルティス ヴァクシンズ アンド ダイアグノスティクス エスアールエル ナイセリアのタンパク質の異種発現
DE60234695D1 (de) * 2001-06-07 2010-01-21 Univ Colorado Mutantenformen von cholera holotoxin als adjuvans
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0302218D0 (en) 2003-01-30 2003-03-05 Chiron Sri Vaccine formulation & Mucosal delivery
AU2003239744B2 (en) * 2002-05-14 2008-07-03 Novartis Vaccines And Diagnostics S.R.L. Mucosal combination vaccines for bacterial meningitis
GB0227346D0 (en) * 2002-11-22 2002-12-31 Chiron Spa 741
ES2397923T3 (es) * 2003-10-02 2013-03-12 Novartis Ag Vacunas líquidas para múltiples serogrupos meningocócicos
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
NZ595234A (en) 2009-03-24 2013-12-20 Novartis Ag Adjuvanting meningococcal factor h binding protein
DK2608805T4 (da) 2010-08-23 2025-06-30 Wyeth Llc STABILE FORMULERINGER AF NEISSERIA MENINGITIDIS rLP2086 ANTIGENER
RU2546873C2 (ru) 2010-09-10 2015-04-10 УАЙТ ЭлЭлСи Нелипидизированные варианты антигенов neisseria meningitidis orf2086
EP2635593B1 (en) * 2010-11-05 2016-09-14 Institut National de la Sante et de la Recherche Medicale (INSERM) Vaccines for preventing meningococcal infections
GB201102090D0 (en) * 2011-02-08 2011-03-23 Univ Sheffield Antigenic polypeptide
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
PE20190458A1 (es) 2012-03-09 2019-04-01 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas
CA2875391A1 (en) 2012-07-27 2014-01-30 Institut National De La Sante Et De La Recherche Medicale Cd147 as receptor for pilus-mediated adhesion of meningococci to vascular endothelia
WO2014136064A2 (en) 2013-03-08 2014-09-12 Pfizer Inc. Immunogenic fusion polypeptides
CA2923129C (en) 2013-09-08 2020-06-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
MX391027B (es) 2015-02-19 2025-03-21 Pfizer Composiciones de neisseria meningitidis y metodos de la misma.
PE20191107A1 (es) 2017-01-31 2019-08-26 Pfizer Composiciones de neisseria meningitidis y metodos respectivos
WO2020124159A1 (en) * 2018-12-21 2020-06-25 Griffith University Compositions, methods and uses for eliciting an immune response
CN115605222A (zh) 2019-09-27 2023-01-13 辉瑞公司（Us） 脑膜炎奈瑟氏菌组合物及其方法
US20220348645A1 (en) * 2019-10-01 2022-11-03 Beth Israel Deaconess Medical Center, Inc. Conformation-specific antibodies that bind nuclear factor kappa-light-chain-enhancer of activated b cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5153312A (en) * 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
JP4472866B2 (ja) * 1997-11-06 2010-06-02 カイロン ソチエタ ア レスポンサビリタ リミタータ ナイセリア抗原
GB9726398D0 (en) * 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
SG152917A1 (en) * 1998-01-14 2009-06-29 Chiron Srl Neisseria meningitidis antigens
MXPA01003228A (es) * 1998-09-30 2003-06-24 American Cyanamid Co Holotoxina de colera mutante como un coadyuvante.
US7384640B1 (en) * 1999-09-30 2008-06-10 Wyeth Holdings Corporation Mutant cholera holotoxin as an adjuvant
AR045702A1 (es) * 2001-10-03 2005-11-09 Chiron Corp Composiciones de adyuvantes.

Also Published As

Publication number Publication date
AU2002353417A1 (en) 2003-06-17
CY1111114T1 (el) 2015-06-11
JP2009155344A (ja) 2009-07-16
CA2468935C (en) 2013-02-05
US20100233205A1 (en) 2010-09-16
ATE485055T1 (de) 2010-11-15
GB0129007D0 (en) 2002-01-23
WO2003047619A3 (en) 2003-10-23
DE60238075D1 (de) 2010-12-02
CA2468935A1 (en) 2003-06-12
JP4414226B2 (ja) 2010-02-10
EP1448230B1 (en) 2010-10-20
JP2005511662A (ja) 2005-04-28
EP1448230A2 (en) 2004-08-25
US20060008476A1 (en) 2006-01-12
WO2003047619A2 (en) 2003-06-12

Similar Documents

Publication Publication Date Title
AP2004003074A0 (en) Adjuvanted antigenic meningococcal compositions
FR11C0001I2 (fr) Vaccins combines contre neisseria meningitidis
MX2007003402A (es) Composicion inmunogena para su uso en vacunacion contra estafilococos.
MXPA05007886A (es) Vacunas para la mucosa con adyuvante de quitosan y antigenos para meningococo.
BR0310042A (pt) Vacinas de combinação mucosal para meningite bacteriana
PT1235589E (pt) Composições compreendendo antigénios da neisseria meningitidis dos serogrupos b e c, e outro antigénio
BRPI0410423A (pt) processo de imunogenicidade melhorada para vacinação meningocócica
NZ562998A (en) Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
AU2457100A (en) Enhancement of bactericidal activity of neisseria antigens with oligonucleotidescontaining cg motifs
MA30065B1 (fr) Vaccin
BR0015961A (pt) Antìgeno de neisseria de 85kda
IL225522A0 (en) A conjugate vaccine of meningococcal polysaccharide and a multivalent protein used to protect a person against infection caused by meningitidis n. and a method for preparing the vaccine
AU2002252638A1 (en) Molecular mimetics of meningococcal b epitopes which elicit functionally active antibodies
HU1000593D0 (en) Vaccine compositions
PT1897555E (pt) Vacina omv suplementada contra meningococos
WO2007026249A3 (en) Multiple vaccination including serogroup c meningococcus
BR0112928A (pt) Vacinas para proteção de amplo espectro contra doenças causadas por neisseria meningitidis
AU2168902A (en) Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol
EA200801368A1 (ru) Конъюгатные вакцины
NZ500159A (en) Detoxified mutants of bacterial adp-ribosylating toxins as parenteral adjuvants
WO2004103400A3 (en) Multivalent meningococcal derivatized polysaccharide-protein conjugates and corresponding vaccines
EP2364725A3 (en) Immunization method against neisseria meningitidis serogroups a and c
WO2001078787A3 (en) Lipopolysaccharide-conjugate vaccine for sepsis treatment
EP1592443A4 (en) IMPROVEMENTS IN VACCINES AGAINST ANTHRAX AND METHODS OF ADMINISTRATION
WO2005023295A3 (en) Naturally processed immunodominant peptides derived from neisseria meningitidis porin a protein and their use